YC W24
Eris Biotech
Our drugs engage the immune system to fight tumors
About
We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.
Founders
- Rachel Garlick
- Evita Weagel
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Eris Biotech.
See family office activityIndustry & Focus
HealthcareTherapeuticsBiotechDrug discoveryOncology